TransMedics Group (NASDAQ:TMDX) Shares Climb 4.2% – What’s Next?

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) traded up 4.2% on Wednesday. The stock traded as high as $83.76 and last traded at $83.6560. 387,111 shares changed hands during trading, a decline of 62% from the average session volume of 1,006,125 shares. The stock had previously closed at $80.28.

Analyst Ratings Changes

TMDX has been the subject of several recent analyst reports. UBS Group cut their price target on shares of TransMedics Group from $80.00 to $77.00 and set a “neutral” rating for the company in a report on Wednesday, August 5th. TD Cowen reiterated a “buy” rating and issued a $120.00 target price on shares of TransMedics Group in a research report on Tuesday, September 8th. Needham & Company LLC reissued a “buy” rating on shares of TransMedics Group in a research note on Friday, September 11th. Weiss Ratings raised shares of TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $124.00 price objective on shares of TransMedics Group in a report on Tuesday, June 30th. Six analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $121.00.

TransMedics Group Price Performance

The stock’s 50-day moving average price is $85.86 and its 200 day moving average price is $84.45. The company has a quick ratio of 6.07, a current ratio of 6.62 and a debt-to-equity ratio of 1.62. The firm has a market capitalization of $2.85 billion, a price-to-earnings ratio of 21.23, a PEG ratio of 1.14 and a beta of 1.94.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Tuesday, August 4th. The company reported $0.44 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.06). TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The business had revenue of $189.95 million during the quarter, compared to analyst estimates of $184.00 million. During the same quarter in the previous year, the company posted $0.92 EPS. The firm’s revenue was up 20.7% on a year-over-year basis. Equities research analysts expect that TransMedics Group, Inc. will post 1.46 earnings per share for the current fiscal year.

Insider Activity

In other TransMedics Group news, Director David Weill purchased 1,336 shares of the stock in a transaction dated Friday, September 11th. The stock was acquired at an average cost of $81.63 per share, for a total transaction of $109,057.68. Following the acquisition, the director owned 16,392 shares in the company, valued at $1,338,078.96. This trade represents a 8.87% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 6.90% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

Several large investors have recently made changes to their positions in TMDX. Goldman Sachs Group Inc. lifted its position in shares of TransMedics Group by 50.1% during the fourth quarter. Goldman Sachs Group Inc. now owns 965,931 shares of the company’s stock worth $117,506,000 after purchasing an additional 322,353 shares in the last quarter. Braidwell LP grew its stake in shares of TransMedics Group by 85.1% in the second quarter. Braidwell LP now owns 609,715 shares of the company’s stock worth $40,497,000 after acquiring an additional 280,324 shares in the last quarter. Deutsche Bank AG acquired a new stake in shares of TransMedics Group in the second quarter valued at $14,415,000. Bank of New York Mellon Corp purchased a new position in TransMedics Group in the second quarter valued at $12,869,000. Finally, Legal & General Group Plc acquired a new stake in TransMedics Group in the second quarter valued at approximately $5,286,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical technology company that develops organ transplant systems designed to preserve and assess donated organs outside the body before transplantation. Its primary platform, the Organ Care System (OCS), uses warm perfusion technology to circulate oxygenated blood and nutrients through organs, helping maintain organ function during transport and potentially expanding the pool of organs available for transplant.

The company offers OCS solutions for heart, lung and liver transplantation.